Horizon Therapeutics Public (NASDAQ:HZNP) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Horizon Therapeutics Public (NASDAQ:HZNP) from a buy rating to a strong-buy rating in a report issued on Wednesday morning.

Separately, Jefferies Financial Group lowered Horizon Therapeutics Public from a buy rating to a hold rating in a research note on Friday, September 1st. Eight investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $110.71.

Horizon Therapeutics Public Stock Performance

Shares of NASDAQ HZNP opened at $115.31 on Wednesday. The stock has a 50 day moving average price of $106.34 and a 200 day moving average price of $106.27. Horizon Therapeutics Public has a 52 week low of $60.03 and a 52 week high of $115.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.09 and a current ratio of 4.27. The stock has a market capitalization of $26.40 billion, a PE ratio of 61.66, a price-to-earnings-growth ratio of 3.50 and a beta of 1.05.

Horizon Therapeutics Public (NASDAQ:HZNP) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.08. The firm had revenue of $945.00 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a return on equity of 20.46% and a net margin of 12.02%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 earnings per share. Analysts predict that Horizon Therapeutics Public will post 4.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Horizon Therapeutics Public

A number of large investors have recently made changes to their positions in HZNP. D.A. Davidson & CO. bought a new position in shares of Horizon Therapeutics Public during the first quarter worth approximately $223,000. Synovus Financial Corp increased its stake in shares of Horizon Therapeutics Public by 8.7% during the first quarter. Synovus Financial Corp now owns 11,196 shares of the biopharmaceutical company’s stock worth $1,181,000 after purchasing an additional 895 shares during the period. Cetera Investment Advisers increased its stake in shares of Horizon Therapeutics Public by 10.2% during the first quarter. Cetera Investment Advisers now owns 2,874 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 267 shares during the period. Vanguard Group Inc. increased its stake in shares of Horizon Therapeutics Public by 0.9% during the first quarter. Vanguard Group Inc. now owns 20,328,877 shares of the biopharmaceutical company’s stock worth $2,138,801,000 after purchasing an additional 190,183 shares during the period. Finally, Loomis Sayles & Co. L P increased its stake in shares of Horizon Therapeutics Public by 3.3% during the first quarter. Loomis Sayles & Co. L P now owns 349,586 shares of the biopharmaceutical company’s stock worth $36,780,000 after purchasing an additional 11,054 shares during the period. Institutional investors own 80.37% of the company’s stock.

Horizon Therapeutics Public Company Profile

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.